BioRestorative Provides Update on its Active Phase 2 Clinical Trial MELVILLE, N.Y., Feb. 07, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies,…
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a…
KELOWNA, British Columbia, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to…
Press releaseMalmö, Sweden, February 7, 2022 Acarix invites to virtual Capital Market Day Acarix is stepping up commercialization and focus…
BURBANK, CA, Feb. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing,…
Elraglusib will be combined with FOLFIRINOX alone or with Losartan in multi-center Phase 2 clinical study initiated at Massachusetts General…
SUWON, Republic of Korea, Feb. 07, 2022 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi…
MIAMI, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring,…
JUPITER, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology…
Call to be held on Monday, February 14th at 1:00 PM Eastern TimeLAVAL, Quebec, Feb. 07, 2022 (GLOBE NEWSWIRE) --…